Nemaura Medical Inc. (NASDAQ: NMRD) Helping Diabetic Individuals Safeguard Themselves From COVID-19

• 1 in 8 adults are forecast to suffer from diabetes by 2024, with over 1 in 10 deaths in 2021 a direct result of the disease
• As many as 40% of Covid-19 related fatalities in the US also suffered from diabetes at the time of their passing
• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• In addition to sugarBEAT, its flagship device, the company also recently announced the launch of MiBoKo, a combined application and non-invasive glucose sensor designed to help users track their metabolic scores

By 2024, the International Diabetes Federation (“IDF”) predicts that the number of people with diabetes is expected to rise to 1 in 8 adults. Nearly 7 million adults have died worldwide in 2021 so far due to diabetes or its related complications – astoundingly, accounting for over 1 in 10 global deaths from any cause. While enormous, that figure does not consider the lives lost to the novel coronavirus, which has shown to be particularly deadly for people with diabetes. A study found that having Type 1 or Type 2 diabetes tripled the risk of severe illness or death from COVID-19 (https://ibn.fm/laj37).

“As many as 40% of the people that have died in the US from COVID-19 had diabetes,” said Dr. Robert Gabbay, chief scientific and medical officer for the American Diabetes Association. 

Founded in 2011, Nemaura Medical (NASDAQ: NMRD),  a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, set out to develop a single platform technology to measure blood markers at the surface of the skin. Since then, the company has evolved by creating wearable technologies and digital health care solutions that encourage and empower people to take charge of their health and well-being.

The company’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help people with diabetes and prediabetes manage their glucose levels. The company has recently followed up with the release of the MiBoKo application. This service, which has been in development for the past 18 months, seeks to address a significant mass-market opportunity which the company believes could benefit roughly a third to half of the global population. The MiBoKo application uses a non-invasive glucose sensor to measure and monitor the user’s metabolic health scores, which are based on glucose tolerance or insulin resistance. Prediabetic patients, those facing obesity concerns, or individuals looking to monitor their glucose intake would all benefit from this application.

A recent study carried out using anonymized health care data from a sample of over 16,000 people with both type 2 diabetes and COVID-19 found that people with type 2 diabetes who contracted Covid-19 were nearly 50% more likely to wind up in intensive care if they had mismanaged their blood sugar levels over the long-term, relative to those with better long-term glycaemic control (https://ibn.fm/8ySDC).

With the COVID-19 virus rapidly gaining endemic status worldwide, diabetic and prediabetic patients are more at risk than ever before. By launching their unique and functional glucose monitoring devices, Nemaura Medical has sought to address this growing health risk, providing individuals afflicted with diabetes the world over with a more accessible, non-invasive method to monitor their health.

For more information, visit the company websites at www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.